To avoid medication errors between APIDRA and other insulins, instruct patients to always check the insulin label before each injection.Īll insulin products, including Apidra, can cause hypokalemia. Hypoglycemia is the most common adverse reaction associated with insulins, including Apidra, and maybe life-threatening. Advise patients to rotate injection site to unaffected areas and closely monitor for hypoglycemia. Repeated insulin injections into areas of lipodystrophy or localized cutaneous amyloidosis may result in hyperglycemia sudden change in the injection site (to unaffected area) has been reported to result in hypoglycemia. Dosing should be individualized based on patient characteristics and lifestyle. Changes in insulin regimen including, strength, manufacturer, type, injection site or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Modify insulin regimens only under medical supervision. Monitor blood glucose in all patients treated with insulin. Insulin pens and needles must never be shared between patients, even if the needle is changed. Apidra is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra or any of its excipients.
